A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
| Status: | Completed |
|---|---|
| Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 2/17/2019 |
| Start Date: | September 2015 |
| End Date: | June 2017 |
A Phase 3, 52-week, Randomized, Active−Controlled Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized TD−4208 in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to measure the safety and tolerability of TD 4208, an
investigational drug being developed to treat people with moderate to very severe COPD,
compared to tiotropium.
investigational drug being developed to treat people with moderate to very severe COPD,
compared to tiotropium.
Inclusion Criteria:
- Subject is a male or female subject 40 years of age or older
Exclusion Criteria:
- Females who are pregnant, lactating, breast-feeding or planning to become pregnant
during the study
We found this trial at
1
site
Easley, South Carolina 29640
Principal Investigator: Andras Koser, MD
Phone: 864-307-1300
Click here to add this to my saved trials
